Atea Pharmaceuticals Stock EBITDA
| AVIR Stock | USD 3.77 0.22 6.20% |
Atea Pharmaceuticals fundamentals help investors to digest information that contributes to Atea Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Atea Stock. The fundamental analysis module provides a way to measure Atea Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Atea Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -119.6 M | -113.6 M |
Atea | EBITDA |
Atea Pharmaceuticals Company EBITDA Analysis
Atea Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Atea Pharmaceuticals EBITDA | (119.59 M) |
Most of Atea Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Atea Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Atea EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Atea Pharmaceuticals is extremely important. It helps to project a fair market value of Atea Stock properly, considering its historical fundamentals such as EBITDA. Since Atea Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Atea Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Atea Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Atea Ebitda
According to the company disclosure, Atea Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (119.59 Million). This is 113.63% lower than that of the Pharmaceuticals sector and 219.41% lower than that of the Health Care industry. The ebitda for all United States stocks is 103.07% higher than that of the company.
Atea EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Atea Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Atea Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Atea Pharmaceuticals by comparing valuation metrics of similar companies.Atea Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Atea Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Atea Pharmaceuticals from analyzing Atea Pharmaceuticals' financial statements. These drivers represent accounts that assess Atea Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Atea Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.5B | 3.4B | 740.4M | 400.4M | 460.5M | 437.4M | |
| Enterprise Value | 2.5B | 2.6B | (23.8M) | (243.2M) | (279.7M) | (265.7M) |
Atea Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Atea Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Atea Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Atea Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Atea Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Atea Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Atea Pharmaceuticals' value.| Shares | Northern Trust Corp | 2024-06-30 | 661.3 K | Two Sigma Advisers, Llc | 2024-06-30 | 612.2 K | Charles Schwab Investment Management Inc | 2024-06-30 | 599.4 K | Dimensional Fund Advisors, Inc. | 2024-06-30 | 594.4 K | Federated Hermes Inc | 2024-06-30 | 571.3 K | Jacobs Levy Equity Management, Inc. | 2024-06-30 | 564.9 K | Citadel Advisors Llc | 2024-06-30 | 525.6 K | Newtyn Management Llc | 2024-06-30 | 380 K | Two Sigma Investments Llc | 2024-06-30 | 375.1 K | Blackrock Inc | 2024-06-30 | 9.1 M | Fmr Inc | 2024-06-30 | 6.4 M |
Atea Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.14 | ||||
| Current Valuation | (200.49 M) | ||||
| Shares Outstanding | 84.42 M | ||||
| Shares Owned By Insiders | 9.67 % | ||||
| Shares Owned By Institutions | 69.60 % | ||||
| Number Of Shares Shorted | 2.78 M | ||||
| Price To Earning | 15.03 X | ||||
| Price To Book | 0.63 X | ||||
| Price To Sales | 1.90 X | ||||
| Gross Profit | (81.94 M) | ||||
| EBITDA | (119.59 M) | ||||
| Net Income | (135.96 M) | ||||
| Cash And Equivalents | 684.48 M | ||||
| Cash Per Share | 8.22 X | ||||
| Total Debt | 2.4 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 27.46 X | ||||
| Book Value Per Share | 5.64 X | ||||
| Cash Flow From Operations | (85.39 M) | ||||
| Short Ratio | 11.01 X | ||||
| Earnings Per Share | (2.10) X | ||||
| Target Price | 6.88 | ||||
| Number Of Employees | 75 | ||||
| Beta | 0.17 | ||||
| Market Capitalization | 320.06 M | ||||
| Total Asset | 594.97 M | ||||
| Retained Earnings | (195.84 M) | ||||
| Working Capital | 558.08 M | ||||
| Current Asset | 97.88 M | ||||
| Current Liabilities | 6.25 M | ||||
| Net Asset | 594.97 M |
About Atea Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Atea Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atea Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atea Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Atea Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Atea Stock
| 0.33 | A | Agilent Technologies Fiscal Year End 18th of November 2024 | PairCorr |
The ability to find closely correlated positions to Atea Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea Pharmaceuticals to buy it.
The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.